These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9. Page MM; Stefanutti C; Sniderman A; Watts GF Clin Sci (Lond); 2015 Jul; 129(1):63-79. PubMed ID: 25881720 [TBL] [Abstract][Full Text] [Related]
8. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia. Rubba P; Gentile M; Marotta G; Iannuzzi A; Sodano M; De Simone B; Jossa F; Iannuzzo G; Giacobbe C; Di Taranto MD; Fortunato G Eur J Prev Cardiol; 2017 Jul; 24(10):1051-1059. PubMed ID: 28353356 [TBL] [Abstract][Full Text] [Related]
9. Homozygous familial hypercholesterolaemia: update on management. France M Paediatr Int Child Health; 2016 Nov; 36(4):243-247. PubMed ID: 27967828 [TBL] [Abstract][Full Text] [Related]
10. Diagnosis and treatment of familial hypercholesterolaemia. Hovingh GK; Davidson MH; Kastelein JJ; O'Connor AM Eur Heart J; 2013 Apr; 34(13):962-71. PubMed ID: 23416791 [TBL] [Abstract][Full Text] [Related]
12. The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease. Kim EJ; Wierzbicki AS Ther Adv Chronic Dis; 2020; 11():2040622320924569. PubMed ID: 32537117 [TBL] [Abstract][Full Text] [Related]
13. Improving the detection of familial hypercholesterolaemia. Lan NSR; Martin AC; Brett T; Watts GF; Bell DA Pathology; 2019 Feb; 51(2):213-221. PubMed ID: 30579649 [TBL] [Abstract][Full Text] [Related]
14. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202 [TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602 [TBL] [Abstract][Full Text] [Related]
17. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management. Miname MH; Santos RD Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498 [TBL] [Abstract][Full Text] [Related]
18. New Horizons in the Pathogenesis, Pathophysiology and Treatment of Familial Hypercholesterolaemia. Viigimaa M; Heinsar S; Lovic D; Katsimardou A; Piperidou A; Duishvili D Curr Pharm Des; 2018; 24(31):3599-3604. PubMed ID: 30306860 [TBL] [Abstract][Full Text] [Related]
19. 6th Hellenic Congress in Athens, of the Hellenic Atherosclerosis Society, on the 04-06 December 2014 Novel Pharmacologic Treatments of Familial Hypercholesterolaemia. Athyros VG Open Cardiovasc Med J; 2015; 9():73-7. PubMed ID: 26664657 [TBL] [Abstract][Full Text] [Related]